[
    [
        {
            "time": "",
            "original_text": "市盈率超65倍、高管减持463亿市值的泰格医药贵吗？",
            "features": {
                "keywords": [
                    "市盈率",
                    "高管减持",
                    "泰格医药"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "市盈率超65倍、高管减持463亿市值的泰格医药贵吗？",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "泰格医药(300347.SZ)回购注销约11.06万股限制性股票",
            "features": {
                "keywords": [
                    "泰格医药",
                    "回购注销",
                    "限制性股票"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "泰格医药(300347.SZ)回购注销约11.06万股限制性股票",
                "Correlation": 10,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "泰格医药(300347.SZ)：ZHUAN YIN拟减持不超80.7万股 拟减持股份",
            "features": {
                "keywords": [
                    "泰格医药",
                    "减持",
                    "股份"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "泰格医药(300347.SZ)：ZHUAN YIN拟减持不超80.7万股 拟减持股份",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "泰格医药：董事及高级管理人员拟减持不超0.11%股份 减持股份",
            "features": {
                "keywords": [
                    "泰格医药",
                    "董事",
                    "高级管理人员",
                    "减持"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "泰格医药：董事及高级管理人员拟减持不超0.11%股份 减持股份",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "泰格医药：变更保荐代表人",
            "features": {
                "keywords": [
                    "泰格医药",
                    "变更",
                    "保荐代表人"
                ],
                "sentiment_score": 0.2,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "泰格医药：变更保荐代表人",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 3,
                "Duration": 4,
                "Entity_Density": 9,
                "Market_Scope": 2,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "继续看好医药核心资产，坚守创新、消费和器械【西南医药|0901周报】",
            "features": {
                "keywords": [
                    "医药",
                    "核心资产",
                    "创新",
                    "消费",
                    "器械"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "继续看好医药核心资产，坚守创新、消费和器械【西南医药|0901周报】",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "【医药】物流运输需求下滑风险，运输结构变化风险",
            "features": {
                "keywords": [
                    "医药",
                    "物流运输",
                    "需求下滑",
                    "风险"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "【医药】物流运输需求下滑风险，运输结构变化风险",
                "Correlation": 3,
                "Sentiment": 3,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 2,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-09-01",
            "original_text": "【医药】江琦、祝嘉琦：医药板块2019H1分析暨9月月报：产业结构调整，子板块分化明显，把握结构性机会-20190901",
            "features": {
                "keywords": [
                    "医药",
                    "产业结构调整",
                    "子板块分化",
                    "结构性机会"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【医药】江琦、祝嘉琦：医药板块2019H1分析暨9月月报：产业结构调整，子板块分化明显，把握结构性机会-20190901",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 4
            }
        }
    ]
]